QUOTE AND NEWS
SeekingAlpha  Aug 11  Comment 
Halozyme Therapeutics (NASDAQ:HALO) Q2 2014 Earnings Call August 11, 2014 4:30 pm ET Executives Schond Greenway - Helen I. Torley - Chief Executive Officer, President and Director David A. Ramsay - Chief Financial Officer,...
Forbes  Aug 8  Comment 
Halozyme Therapeutics is expected to book a narrower loss than a year ago when it reports second-quarter earnings on Monday, August 11, 2014. Analysts are expecting a loss of 18 cents per share, up from a loss of 20 cents per share a year...
FierceBiotech  Aug 1  Comment 
A group of FDA advisers has given its blessing to a previously rejected immunodeficiency treatment from Baxter and Halozyme Therapeutics, setting the stage for an approval after years of delay.
Benzinga  Jul 31  Comment 
Halozyme Therapeutics (NASDAQ: HALO) received notice Thursday that the Blood Products Advisory Committee (BPAC) of the U.S. Food and Drug Administration voted in favor of HyQvia, which it was working with along with Baxter (NYSE: BAX). The...
Benzinga  Jul 22  Comment 
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it has resumed enrollment and dosing of patients in its ongoing Phase 2 trial (Study 202) evaluating PEGPH20 in patients with pancreatic cancer under the revised clinical protocol...
StreetInsider.com  Jul 22  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Halozyme+Therapeutics+%28HALO%29+Continues+Enrollment+in+PEGPH20+Phase+2/9678556.html for the full story.
Benzinga  Jul 11  Comment 
Analysts at JP Morgan initiated coverage on Halozyme Therapeutics (NASDAQ: HALO) with a Outperform rating. The target price for Halozyme Therapeutics is set to $13. Halozyme Therapeutics shares have gained 10.07% over the past 52 weeks,...
StreetInsider.com  Jun 25  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Halozyme+Therapeutics+%28HALO%29+Reports+Milestone+Triggered+with+MabThera+SC+Launch+in+Europe/9611816.html for the full story.
Motley Fool  Jun 12  Comment 
Halozyme shares shoot higher after receiving positive commentary from a Wall Street firm.
TheStreet.com  Jun 12  Comment 
NEW YORK (TheStreet) -- RATINGS CHANGES Halozyme Therapeutics was upgraded at UBS to buy from neutral, UBS said. Driven on pipeline potential and undervalued valuation, UBS said. Twelve-month price target is $16. Hewlett-Packard was upgraded...





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki